Perrigo Company plc Proceeds from Income Tax Refunds
Perrigo Company plc (PRGO) reported Proceeds from Income Tax Refunds of $20.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIncomeTaxRefunds · last filed 2026-02-26
- Perrigo Company plc proceeds from income tax refunds for the quarter ending 2016-12-31 was $3.30M, a 371.43% increase year-over-year.
- Perrigo Company plc proceeds from income tax refunds for the quarter ending 2016-10-01 was $5.70M, a 470.00% increase year-over-year.
- Perrigo Company plc proceeds from income tax refunds for the quarter ending 2016-07-02 was $100.00K, a 80.00% decline year-over-year.
- Perrigo Company plc proceeds from income tax refunds for the quarter ending 2016-04-02 was $200.00K, a 87.50% decline year-over-year.
- Perrigo Company plc proceeds from income tax refunds for fiscal 2025 was $20.20M, a 676.92% increase from fiscal 2024.
- Perrigo Company plc proceeds from income tax refunds for fiscal 2024 was $2.60M, a 75.70% decline from fiscal 2023.
- Perrigo Company plc proceeds from income tax refunds for fiscal 2023 was $10.70M, a 214.71% increase from fiscal 2022.
- Perrigo Company plc proceeds from income tax refunds for fiscal 2022 was $3.40M, a 80.12% decline from fiscal 2021.
| Period end | Proceeds from Income Tax Refunds 3 month | Proceeds from Income Tax Refunds 6 month | Proceeds from Income Tax Refunds 9 month | Proceeds from Income Tax Refunds 12 month |
|---|---|---|---|---|
| 2025-12-31 | $20.20M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $2.60M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $10.70M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $3.40M 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $17.10M 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $38.30M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $28.00M 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $5.10M 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $3.60M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $3.30M derived: 10-K 12 month − 10-Q/A 9 month · filed 2019-02-27 | $9.00M derived: sum of 2 quarters · filed 2019-02-27 | $9.10M derived: sum of 3 quarters · filed 2019-02-27 | $9.30M 10-K · filed 2019-02-27 |
| 2016-10-01 | $5.70M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-05-23 | $5.80M derived: sum of 2 quarters · filed 2017-05-23 | $6.00M 10-Q/A · filed 2017-05-23 | $6.70M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-07-02 | $100.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22 | $300.00K 10-Q/A · filed 2017-05-22 | $1.00M derived: sum of 3 quarters · filed 2018-03-01 | $2.00M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-04-02 | $200.00K 10-Q/A · filed 2017-05-22 | $900.00K derived: sum of 2 quarters · filed 2018-03-01 | $1.90M derived: sum of 3 quarters · filed 2018-03-01 | $2.40M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $700.00K derived: 10-K 6 month − 10-Q 3 month · filed 2018-03-01 | $1.70M 10-K · filed 2018-03-01 | $2.20M derived: sum of 3 quarters · filed 2018-03-01 | $3.80M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-09-26 | $1.00M 10-Q · filed 2015-11-02 | $1.50M derived: sum of 2 quarters · filed 2017-05-22 | $3.10M 10-Q/A · filed 2017-05-23 | $10.10M derived: sum of 4 quarters · filed 2017-05-22 |
| 2015-06-27 | $500.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22 | $2.10M 10-Q/A · filed 2017-05-22 | $9.10M derived: sum of 3 quarters · filed 2017-05-22 | $9.60M 10-K · filed 2018-03-01 |
| 2015-03-28 | $1.60M 10-Q/A · filed 2017-05-22 | $8.60M derived: sum of 2 quarters · filed 2017-05-22 | $9.10M 10-Q · filed 2015-04-29 | $9.80M derived: sum of 4 quarters · filed 2017-05-22 |
| 2014-12-27 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-05 | $7.50M 10-Q · filed 2015-02-05 | $8.20M derived: sum of 3 quarters · filed 2017-05-22 | $8.20M derived: sum of 4 quarters · filed 2017-05-22 |
| 2014-09-27 | $500.00K 10-Q · filed 2015-11-02 | $1.20M derived: sum of 2 quarters · filed 2017-05-22 | $1.20M derived: sum of 3 quarters · filed 2017-05-22 | $4.00M derived: sum of 4 quarters · filed 2017-05-22 |
| 2014-06-28 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $700.00K derived: sum of 2 quarters · filed 2017-05-22 | $3.50M derived: sum of 3 quarters · filed 2017-05-22 | $4.30M 10-K · filed 2017-05-22 |
| 2014-03-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29 | $2.80M derived: sum of 2 quarters · filed 2015-04-29 | $3.60M 10-Q · filed 2015-04-29 | $3.60M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-28 | $2.80M derived: 10-Q 6 month − 8-K 3 month · filed 2015-02-05 | $3.60M 10-Q · filed 2015-02-05 | $3.60M derived: sum of 3 quarters · filed 2016-02-25 | $3.70M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-09-28 | $800.00K 8-K · filed 2014-11-20 | $800.00K derived: sum of 2 quarters · filed 2016-02-25 | $900.00K derived: sum of 3 quarters · filed 2016-02-25 | |
| 2013-06-29 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $100.00K derived: sum of 2 quarters · filed 2016-02-25 | $1.30M 10-KT · filed 2016-02-25 | |
| 2013-03-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07 | $1.30M 10-Q · filed 2014-05-07 | ||
| 2012-12-29 | $1.20M 10-Q · filed 2014-02-06 | |||
| 2012-06-30 | $900.00K 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |